External validation of sTWEAK as a prognostic noninvasive biomarker for head and neck squamous cell carcinoma
Por:
Terra, X, Gomez, D, Garcia-Lorenzo, J, Flores, JC, Figuerola, E, Mora, J, Chacon, MR, Quer, M, Camacho, M, Leon, X, Aviles-Jurado, FX
Publicada:
1 abr 2016
Resumen:
Background. The main purpose of this study was to validate the prognostic significance of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) in head and neck squamous cell carcinoma (HNSCC) using an independent cohort.
Methods. Data were evaluated from 153 patients with HNSCC in stages III to IV, who received radiotherapy (RT) or chemoradiotherapy. We quantified soluble TWEAK (sTWEAK) in pretreatment samples using enzyme-linked immunosorbent assay.
Results. The classification tree revealed a cutoff value of 322 pg/mL for sTWEAK to be ideal for discriminating between patients' disease control. Kaplan-Meier curves indicate that the disease-free survival rate in patients with high sTWEAK was significantly higher than in patients with low levels (p=.006, log-rank test). An independent link was identified between low sTWEAK and poor clinical outcome in Cox regression multivariate analysis (hazard ratio = 1.866; 95% confidence interval [CI] = 1.114-3.125; p = .001).
Conclusion. Our study highlights the significance of this noninvasive biomarker in the discrimination according to the disease control achieved by patients who received a nonsurgical organ-preservation treatment. (C) 2015 Wiley Periodicals, Inc.
Filiaciones:
Terra, X:
Univ Rovira & Virgili, Dept Biochem & Biotechnol, MoBioFood Res Grp, Campus Sescel Lades, E-43007 Tarragona, Spain
Gomez, D:
Hosp St Joan Reus, Dept Radiat Oncol, Reus, Tarragona, Spain
Garcia-Lorenzo, J:
Univ Autonoma Barcelona, Otorhinolaryngol Head Neck Surg Dept, Hosp St Pau, E-08193 Barcelona, Spain
Univ Autonoma Barcelona, Lab Angiol Vasc Biol & Inflammat, Inst Biomed Res IIB St Pau, E-08193 Barcelona, Spain
Flores, JC:
Univ Rovira & Virgili, IISPV, Hosp Univ Tarragona Joan 23, Otorhinolaryngol Head Neck Surg Dept, E-43007 Tarragona, Catalonia, Spain
Figuerola, E:
Univ Rovira & Virgili, IISPV, Hosp Univ Tarragona Joan 23, Otorhinolaryngol Head Neck Surg Dept, E-43007 Tarragona, Catalonia, Spain
Univ Rovira & Virgili, Otolaryngol Dis Res Grp HJ23, Inst Invest Sanitaria Pere Virgili, E-43007 Tarragona, Catalonia, Spain
Mora, J:
Univ Autonoma Barcelona, Hosp St Pau, Biochem Dept, E-08193 Barcelona, Spain
Chacon, MR:
Univ Rovira & Virgili, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Hosp Univ Joan Tarragona 23, Inst Invest Sanitaria Pere Virgili, E-43007 Tarragona, Spain
Quer, M:
Univ Autonoma Barcelona, Otorhinolaryngol Head Neck Surg Dept, Hosp St Pau, E-08193 Barcelona, Spain
Camacho, M:
Univ Autonoma Barcelona, Lab Angiol Vasc Biol & Inflammat, Inst Biomed Res IIB St Pau, E-08193 Barcelona, Spain
Leon, X:
Univ Autonoma Barcelona, Otorhinolaryngol Head Neck Surg Dept, Hosp St Pau, E-08193 Barcelona, Spain
Univ Autonoma Barcelona, Lab Angiol Vasc Biol & Inflammat, Inst Biomed Res IIB St Pau, E-08193 Barcelona, Spain
Univ Autonoma Barcelona, Networking Res Ctr Bioengn Biomat & Nanomed CIBER, MICINN, ISCIII, E-08193 Barcelona, Spain
Aviles-Jurado, FX:
Univ Rovira & Virgili, IISPV, Hosp Univ Tarragona Joan 23, Otorhinolaryngol Head Neck Surg Dept, E-43007 Tarragona, Catalonia, Spain
Univ Rovira & Virgili, Otolaryngol Dis Res Grp HJ23, Inst Invest Sanitaria Pere Virgili, E-43007 Tarragona, Catalonia, Spain
|